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Background: In the Platelet Inhibition and Patients Outcomes trial (PLATO) of 18,624 acute coronary syndrome (ACS) patients, ticagrelor (T) 
compared to clopidogrel (C) significantly reduced the risk of CV death more than that of myocardial infarction (MI). There were numerically also 
fewer non-CV deaths in the ticagrelor group. The mechanisms underlying the significant mortality reduction by ticagrelor are uncertain. Previous 
observational studies have shown increased risk of MI and stroke following a diagnosis of lower respiratory tract infection (LRTI).
Methods: Post hoc analyses were conducted on the safety population who received at least 1 dose of study medication (9235 T, 9186 C) to look 
for associations with mortality, including an analysis of the incidence of pulmonary adverse events (PAE), consisting of the terms LRTI, ‘pneumonia’, 
‘lung infection’, ‘respiratory failure’ and ‘pleural disorders’, occurring not later than 7 days after last dose of study medication. Following a PAE, the 
incidence of MI, stroke, death and sepsis were determined. Fisher’s exact test was used to compare groups.
Results: 275 T (3.0%) and 331 C (3.6%) patients had a PAE with onset not later than 7 days after the last dose of study medication (P = 0.019). 
Following the PAE, a sepsis AE occurred in 8 T and 19 C patients (P = 0.035) and 33 T vs 71 C patients died (P < 0.001) with 21 T vs 42 C deaths 
occurring within 7 days of last dose of study drug (P = 0.008) and 10 T vs 43 C deaths occurring in those who continued study drug for at least 
3 days after PAE onset (P < 0.001). Also following the PAE, death was attributed to sepsis in 1 T vs 10 C patients (P = 0.006). In the entire safety 
population, death was attributed to sepsis in 7 T (0.1%) vs 23 C (0.3%) patients (P = 0.003).
Conclusions: This post hoc analysis suggests that ACS patients treated with T vs C are less likely to develop LRTI and sepsis, and may have less 
frequent adverse outcomes afterwards, including lower mortality. Further studies are warranted to explore potential mechanisms for differential 
effects of T vs C on susceptibility to LRTI and sepsis and their associated mortality.
